{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:23:29Z","timestamp":1767961409635,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.ymgme.2005.01.007","type":"journal-article","created":{"date-parts":[[2005,4,28]],"date-time":"2005-04-28T13:14:30Z","timestamp":1114694070000},"page":"196-202","source":"Crossref","is-referenced-by-count":53,"title":["Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry"],"prefix":"10.1016","volume":"85","author":[{"given":"Teruo","family":"Kitagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Ishige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misao","family":"Owada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahisa","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikatsu","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akemi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Winchester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Keutzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2005.01.007_bib1","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","volume":"vol. 3","author":"Desnick","year":"2001"},{"issue":"Suppl. 8","key":"10.1016\/j.ymgme.2005.01.007_bib2","first-page":"317","article-title":"Lysosomal storage disease. Report of Clinical Statistics of Japan(2)","volume":"59","author":"Owada","year":"2001","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.ymgme.2005.01.007_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of \u03b1-galactosidase A reduces tissue globotriaosyl-ceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymgme.2005.01.007_bib4","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ymgme.2005.01.007_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2005.01.007_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2005.01.007_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"for the International Fabry Disease Study Group, Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2005.01.007_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ndt\/18.1.33","article-title":"Enzyme replacement therapy in Anderson\u2013Fabry\u2019s disease: beneficial clinical effect on vital organ function","volume":"18","author":"Schoenmakere","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2005.01.007_bib9","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00041552-200403000-00012","article-title":"Renoprotection by enzyme replacement therapy","volume":"13","author":"Brenner","year":"2004","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.ymgme.2005.01.007_bib10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/bmj.297.6653.872","article-title":"Anderson\u2013Fabry disease","volume":"297","author":"Morgan","year":"1988","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ymgme.2005.01.007_bib11","first-page":"1","article-title":"Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry","volume":"25919","author":"Mills","year":"2002","journal-title":"FEBS Lett."},{"issue":"Suppl .2","key":"10.1016\/j.ymgme.2005.01.007_bib12","first-page":"157","article-title":"Pilot study of mass-screening for Fabry\u2019s disease (FD) by measuring globotriaosylceramide (GL-3) in whole urine samples using tandem mass spectrometry (TMS)","volume":"26","author":"Kitagawa","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2005.01.007_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2005.01.007_bib14","unstructured":"A. Tanaka, T. Seto, E. Ishimura, S. Sakai, G. Iishiki, Case report: female heterozygote of Fabry disease whose clinical symptoms were limited to proteinuria and microhematuria, in: The 4th Annual Meeting of the Japanese Society for Lipidoses and International Symposium of Lipidoses and Allied Disorders. Program and Abstract, Tokyo, Japan, July 9\u201310, 1998, p. 8 (in Japanese)."},{"key":"10.1016\/j.ymgme.2005.01.007_bib15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1542\/peds.43.2.201","article-title":"Urinary glycolipids in Fabry\u2019s disease. Their examination in the detection of atypical variants and the presymptomatic state","volume":"43","author":"Philippart","year":"1969","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2005.01.007_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-2275(20)43013-5","article-title":"A method for the quantitative determination of neutral glycosphingolipids in urine sediments","volume":"11","author":"Desnick","year":"1970","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymgme.2005.01.007_bib17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJM197104082841401","article-title":"Diagnosis of glycosphingolipidoses by urinary-sediment analysis","volume":"284","author":"Desnick","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2005.01.007_bib18","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1212\/WNL.32.10.1139","article-title":"Fabry disease: detection of heterozygotes by examination of glycolipids in urinary sediment","volume":"32","author":"Cable","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2005.01.007_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0005-2760(96)00175-0","article-title":"Blood group B glycosphingolipids in \u03b1-galactosidase deficiency (Fabry disease): influence of secretor status","volume":"1345","author":"Ledvinova","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2005.01.007_bib20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1006\/abio.1998.2966","article-title":"Quantitative determination of globotriaosylceramide by immunodetection of glycolipid-bound recombinant verotoxin B subunit","volume":"267","author":"Zeidner","year":"1999","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2005.01.007_bib21","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/rcm.728","article-title":"Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson\u2013Fabry disease","volume":"16","author":"Boscaro","year":"2002","journal-title":"Rapid Commun. Mass Spectrum"},{"key":"10.1016\/j.ymgme.2005.01.007_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0009-8981(67)90280-X","article-title":"Analysis of polar lipids in the urine sediments","volume":"16","author":"Wherrett","year":"1967","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2005.01.007_bib23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease. Influence of \u03b1-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine"},{"key":"10.1016\/j.ymgme.2005.01.007_bib24","doi-asserted-by":"crossref","first-page":"PC3148","DOI":"10.1016\/S0021-9258(18)51888-3","article-title":"Fabry\u2019s disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid","volume":"238","author":"Sweely","year":"1963","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2005.01.007_bib25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/0005-2760(66)90012-9","article-title":"Neutral glycolipids of human kidney. Isolation, identification and fatty acid composition","volume":"116","author":"Martensson","year":"1966","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2005.01.007_bib26","first-page":"35","article-title":"A study on glycolipids in Fabry\u2019s disease","volume":"39","author":"Makita","year":"1969","journal-title":"Jpn. J. Exp. Med."},{"key":"10.1016\/j.ymgme.2005.01.007_bib27","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1016\/S0021-9258(19)44007-6","article-title":"Characterization of a blood group B glycolipid accumulating in the pancreas of a patient with Fabry\u2019s disease","volume":"248","author":"Wherrett","year":"1973","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2005.01.007_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/190372a0","article-title":"Gene action in the X-chromosome of the mouse (Mus musculus L.)","volume":"190","author":"Lyon","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.ymgme.2005.01.007_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5414\/CNP57001","article-title":"Enzyme replacement therapy for Fabry disease, an inherited nephropathy","volume":"57","author":"Desnick","year":"2002","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ymgme.2005.01.007_bib30","first-page":"784","article-title":"Identification of point mutations in the \u03b1-galactosidase A gene in classical and atypical hemizygotes with Fabry disease","volume":"47","author":"Sakuraba","year":"1990","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2005.01.007_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00207037","article-title":"Point mutations in the upstream region of the \u03b1-galactosidase A gene exon 6 in an atypical variant of Fabry disease","volume":"89","author":"Ishii","year":"1992","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymgme.2005.01.007_bib32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/0046-8177(90)90258-7","article-title":"Restricted accumulation of globotriaosylceramide in the hearts of atypical case of Fabry\u2019s disease","volume":"21","author":"Ogawa","year":"1990","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ymgme.2005.01.007_bib33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000060184","article-title":"Fabry disease \u03b1-galactosidase A deficiency): renal involvement and enzyme replacement therapy","volume":"136","author":"Desnick","year":"2001","journal-title":"Contrib. Nephrol. Basel, Karger"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719205000466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719205000466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T02:52:11Z","timestamp":1683082331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719205000466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S1096719205000466"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2005.01.007","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}